3-(benzofuran-2-yl)-5-(4-chlorophenyl)-4,5-dihydropyrazole-1-carbothioamide | 1160579-03-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: 3-(benzofuran-2-yl)-5-(4-chlorophenyl)-4,5-dihydropyrazole-1-carbothioamide
• 英文别名: 5-(1-Benzofuran-2-yl)-3-(4-chlorophenyl)-3,4-dihydropyrazole-2-carbothioamide
• CAS: 1160579-03-2
• 化学式: C₁₈H₁₄ClN₃OS
• 分子量: 355.848
• InChiKey: VDUIVKIWQRPGRZ-UHFFFAOYSA-N

物化性质

• 熔点：
  217-218 °C(Solvent: Ethanol)
• 沸点：
  523.4±60.0 °C(predicted)
• 密度：
  1.45±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  86.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(benzofuran-2-yl)-5-(4-chlorophenyl)-4,5-dihydropyrazole-1-carbothioamide 、 2-溴苯乙酮 以 乙醇 为溶剂， 反应 1.0h， 以90%的产率得到3-(benzofuran-2-yl)-5-(4-chlorophenyl)-4,5-dihydro-1-(4-phenylthiazol-2-yl)-1H-pyrazole
  参考文献：
  名称：

  Synthesis and antimicrobial evaluation of 1-(benzofuran-2-yl)-4-nitro-3-arylbutan-1-ones and 3-(benzofuran-2-yl)-4,5-dihydro-5-aryl-1-[4-(aryl)-1,3-thiazol-2-yl]-1H-pyrazoles

  摘要：

  2-Acetylbenzofuran 1 on treatment with substituted aldehydes affords the corresponding chalcones 2a-c. Treatment of the chalcones with nitromethane under Michael addition condition furnished the corresponding Michael adducts 3a-c. Cyclocondensation of the chalcones 2a and 2b with thiosemicarbazide under basic refluxing conditions gave 3-(benzofuran-2-yl)-5-(4-aryl)-4,5-dihydropyrazole-1-carbothioamides 4a,b. The pyrazolines 7a-d were synthesized by treating 4a,b with phenacyl bromides in refluxing ethanol. All the synthesized compounds were screened for their antibacterial and antifungal activities at 100 mu g concentration. Some of our compounds showed excellent antimicrobial activities than control drugs. (C) 2008 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2008.09.029
• 作为产物：
  描述：

  1-(2-Benzofuranyl)-3-(4-chlorophenyl)-2-propen-1-one 、 氨基硫脲 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 6.0h， 以86%的产率得到3-(benzofuran-2-yl)-5-(4-chlorophenyl)-4,5-dihydropyrazole-1-carbothioamide
  参考文献：
  名称：

  Synthesis and antimicrobial evaluation of 1-(benzofuran-2-yl)-4-nitro-3-arylbutan-1-ones and 3-(benzofuran-2-yl)-4,5-dihydro-5-aryl-1-[4-(aryl)-1,3-thiazol-2-yl]-1H-pyrazoles

  摘要：

  2-Acetylbenzofuran 1 on treatment with substituted aldehydes affords the corresponding chalcones 2a-c. Treatment of the chalcones with nitromethane under Michael addition condition furnished the corresponding Michael adducts 3a-c. Cyclocondensation of the chalcones 2a and 2b with thiosemicarbazide under basic refluxing conditions gave 3-(benzofuran-2-yl)-5-(4-aryl)-4,5-dihydropyrazole-1-carbothioamides 4a,b. The pyrazolines 7a-d were synthesized by treating 4a,b with phenacyl bromides in refluxing ethanol. All the synthesized compounds were screened for their antibacterial and antifungal activities at 100 mu g concentration. Some of our compounds showed excellent antimicrobial activities than control drugs. (C) 2008 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2008.09.029

文献信息

• Synthesis and antimicrobial evaluation of 1-(benzofuran-2-yl)-4-nitro-3-arylbutan-1-ones and 3-(benzofuran-2-yl)-4,5-dihydro-5-aryl-1-[4-(aryl)-1,3-thiazol-2-yl]-1H-pyrazoles
  作者：Bakr F. Abdel-Wahab、Hatem A. Abdel-Aziz、Essam M. Ahmed

  DOI：10.1016/j.ejmech.2008.09.029

  日期：2009.6

  2-Acetylbenzofuran 1 on treatment with substituted aldehydes affords the corresponding chalcones 2a-c. Treatment of the chalcones with nitromethane under Michael addition condition furnished the corresponding Michael adducts 3a-c. Cyclocondensation of the chalcones 2a and 2b with thiosemicarbazide under basic refluxing conditions gave 3-(benzofuran-2-yl)-5-(4-aryl)-4,5-dihydropyrazole-1-carbothioamides 4a,b. The pyrazolines 7a-d were synthesized by treating 4a,b with phenacyl bromides in refluxing ethanol. All the synthesized compounds were screened for their antibacterial and antifungal activities at 100 mu g concentration. Some of our compounds showed excellent antimicrobial activities than control drugs. (C) 2008 Elsevier Masson SAS. All rights reserved.